Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Trial to Investigate the Safety of C13-CAC and the Relationship Among C13-CAC Breath Test, Gastric pH, and the Improvement of Symptoms in PPI Resistant GERD Patients

NCT03284177 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03284177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03284177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Trial to Investigate the Safety of C13-CAC and the Relationship Among C13-CAC Breath Test, Gastric pH, and the Improvement of Symptoms in PPI Resistant GERD Patients
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2017
Completion date
December 4, 2018
Enrollment
55 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease